CN100582121C - 胸腺素β4衍生物及其应用 - Google Patents

胸腺素β4衍生物及其应用 Download PDF

Info

Publication number
CN100582121C
CN100582121C CN200680025339A CN200680025339A CN100582121C CN 100582121 C CN100582121 C CN 100582121C CN 200680025339 A CN200680025339 A CN 200680025339A CN 200680025339 A CN200680025339 A CN 200680025339A CN 100582121 C CN100582121 C CN 100582121C
Authority
CN
China
Prior art keywords
ala
gly
group
thymosin
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200680025339A
Other languages
English (en)
Chinese (zh)
Other versions
CN101218249A (zh
Inventor
聂李亚
马素永
许松山
文美玉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BEIJING NORTHLAND BIOTECHNOLOGY Co Ltd
Original Assignee
Beijing Northland Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN 200510083894 external-priority patent/CN1896096A/zh
Priority claimed from CNB2005101032937A external-priority patent/CN100484957C/zh
Application filed by Beijing Northland Biotech Co Ltd filed Critical Beijing Northland Biotech Co Ltd
Publication of CN101218249A publication Critical patent/CN101218249A/zh
Application granted granted Critical
Publication of CN100582121C publication Critical patent/CN100582121C/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57581—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN200680025339A 2005-07-15 2006-07-14 胸腺素β4衍生物及其应用 Active CN100582121C (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN200510083894.6 2005-07-15
CN 200510083894 CN1896096A (zh) 2005-07-15 2005-07-15 基因工程方法生产的高活性胸腺素β4衍生物
CNB2005101032937A CN100484957C (zh) 2005-09-23 2005-09-23 胸腺素β4衍生物及其应用
CN200510103293.7 2005-09-23
PCT/CN2006/001679 WO2007009359A1 (en) 2005-07-15 2006-07-14 Thymosin beta 4 derivatives and use thereof

Publications (2)

Publication Number Publication Date
CN101218249A CN101218249A (zh) 2008-07-09
CN100582121C true CN100582121C (zh) 2010-01-20

Family

ID=37668439

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200680025339A Active CN100582121C (zh) 2005-07-15 2006-07-14 胸腺素β4衍生物及其应用

Country Status (7)

Country Link
US (1) US7816321B2 (enExample)
EP (1) EP1908779B1 (enExample)
JP (1) JP5180074B2 (enExample)
KR (1) KR100984635B1 (enExample)
CN (1) CN100582121C (enExample)
PL (1) PL1908779T3 (enExample)
WO (1) WO2007009359A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106692949A (zh) * 2016-12-23 2017-05-24 北京诺思兰德生物技术股份有限公司 一种用于治疗眼部疾病的药物及其组合物

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007014253A2 (en) * 2005-07-26 2007-02-01 Regenerx Biopharmaceuticals, Inc. Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure
GB2476789A (en) 2009-11-10 2011-07-13 Gl Holdings Inc Bv Use of thymosin for treatment of type 2 diabetes
US9504730B2 (en) 2010-09-30 2016-11-29 Regenerx Biopharmaceuticals, Inc. Method of achieving a thymosin beta 4 concentration in a human patient
WO2012126047A1 (en) * 2011-03-18 2012-09-27 Adistem Ltd Agent and method for treating pain and reducing inflammation
CN103724422B (zh) * 2014-01-13 2015-10-21 哈尔滨吉象隆生物技术有限公司 一种裂解胸腺素β4的方法
CN104311672B (zh) * 2014-10-21 2017-07-11 中国药科大学 一种具有肿瘤细胞靶向性的抑制剂多肽
KR101910908B1 (ko) * 2017-06-14 2018-10-24 (주)휴온스 Gly-Tβ4 (Gly-티모신β4)을 함유하는 안구건조증 치료용 약학적 조성물
KR101946789B1 (ko) * 2018-01-26 2019-02-12 (주)휴온스 이황화결합 이성질화효소 신호 펩타이드를 포함하는 재조합 벡터 및 이의 용도
WO2019178059A1 (en) * 2018-03-13 2019-09-19 Georgetown University ENHANCING CHEMOTHERAPY IN MEDULLOBLASTOMA AND GLIOBLASTOMA WITH HIGH BASAL p53 LEVELS
KR102140531B1 (ko) * 2018-08-07 2020-08-04 (주)휴온스 Gly-Tβ4의 제조방법
CN108853483B (zh) * 2018-08-10 2022-03-15 北京诺思兰德生物技术股份有限公司 经修饰的胸腺素β4在治疗脑缺血再灌注损伤方面的用途
CN110215513B (zh) * 2018-11-15 2022-02-22 北京诺思兰德生物技术股份有限公司 经修饰的胸腺素β4在治疗放射性肠炎方面的用途
CN109865127B (zh) * 2018-11-22 2022-03-04 北京诺思兰德生物技术股份有限公司 经修饰的胸腺素β4在治疗糖尿病周围神经病变方面的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4297276A (en) * 1979-03-23 1981-10-27 Hoffman-La Roche Inc. Thymosin beta 3 and beta 4
US4395404A (en) * 1982-05-14 1983-07-26 George Washington University Synthetic thymosin β3 and β4 analogues

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1591128A1 (en) * 1998-07-30 2005-11-02 The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health Thymosin beta 4 promotes wound repair
ATE466868T1 (de) 2005-04-20 2010-05-15 Viromed Co Ltd Zusammensetzungen und verfahren zur trennung von fusionsproteinen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4297276A (en) * 1979-03-23 1981-10-27 Hoffman-La Roche Inc. Thymosin beta 3 and beta 4
US4395404A (en) * 1982-05-14 1983-07-26 George Washington University Synthetic thymosin β3 and β4 analogues

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Structural requirements for thymosin β4 in its contact withactin. Simenel C et al.Eur, J. Biochem,,Vol.2000 No.267. 2000
Structural requirements for thymosin β4 in its contact withactin. Simenel C et al.Eur,J.Biochem,Vol.2000 No.267. 2000 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106692949A (zh) * 2016-12-23 2017-05-24 北京诺思兰德生物技术股份有限公司 一种用于治疗眼部疾病的药物及其组合物
CN106692949B (zh) * 2016-12-23 2022-03-15 北京诺思兰德生物技术股份有限公司 一种用于治疗眼部疾病的药物及其组合物

Also Published As

Publication number Publication date
EP1908779A1 (en) 2008-04-09
JP5180074B2 (ja) 2013-04-10
KR100984635B1 (ko) 2010-10-01
EP1908779A4 (en) 2009-09-30
KR20080040708A (ko) 2008-05-08
US20090298758A1 (en) 2009-12-03
JP2009500045A (ja) 2009-01-08
PL1908779T3 (pl) 2013-06-28
EP1908779B1 (en) 2013-01-09
US7816321B2 (en) 2010-10-19
CN101218249A (zh) 2008-07-09
WO2007009359A1 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
CN100582121C (zh) 胸腺素β4衍生物及其应用
EP2552470B1 (en) Peptides for promoting angiogenesis and an use thereof
MX2014009129A (es) Polipeptidos de factor 15 de diferenciacion de crecimiento (gdf-15).
JPH05255392A (ja) Ａ−ｃ−ｂプロインスリン、その製造法および使用法、およびインスリン生産の中間体
JPH01156998A (ja) 血清担体タンパク質との結合力が減少しているヒトインスリン様成長因子類以体及び酵母におけるそれらの産生
JPH04503808A (ja) 新規インシュリン化合物
KR20120082909A (ko) 합성 마이오스타틴 펩티드 길항제
CN114380919B (zh) 经修饰的il-2分子及其用途
US11578112B2 (en) Long-acting adrenomedullin derivative conjugated with Fc region of immunoglobulin
JP2016536306A (ja) ヒト・リラキシン類似体、その医薬組成物及びその医薬用途
EP1587526B1 (en) Mntf peptides and compositions and methods of use
US9249185B2 (en) Peptides for promoting angiogenesis and an use thereof
CN100484957C (zh) 胸腺素β4衍生物及其应用
PT1506295E (pt) Muteínas do factor de crescimento placentário do tipo 1, processo de preparação e sua aplicação
JP2006508695A (ja) 単量体インスリン
JPS62501071A (ja) 成長因子活性を有する新規なポリペプチド及び該ポリペプチドをコ−ドする核酸配列
CN102675449B (zh) 缺失型人角质细胞生长因子-ⅰ二硫键变构体及其用途
KR20130032787A (ko) 심혈관 질환 예방 및 치료용 펩타이드 및 이의 용도

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: 100085 Beijing Road, Haidian District, No. 5 Zhongguancun biomedical park room A402

Patentee after: Beijing Northland Biotechnology Co., Ltd.

Address before: 100085 Beijing Road, Haidian District, No. 5 Zhongguancun biomedical park room A402

Patentee before: Beijing Northland Biotech. Co., Ltd.

PE01 Entry into force of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Thymosin beta4 derivative and itsuse

Effective date of registration: 20170329

Granted publication date: 20100120

Pledgee: Beijing technology intellectual property financing Company limited by guarantee

Pledgor: Beijing Northland Biotechnology Co., Ltd.

Registration number: 2017990000253

PC01 Cancellation of the registration of the contract for pledge of patent right
PC01 Cancellation of the registration of the contract for pledge of patent right

Date of cancellation: 20200410

Granted publication date: 20100120

Pledgee: Beijing technology intellectual property financing Company limited by guarantee

Pledgor: BEIJING NORTHLAND BIOTECH Co.,Ltd.

Registration number: 2017990000253

PE01 Entry into force of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Thymosin beta4 derivative and itsuse

Effective date of registration: 20200628

Granted publication date: 20100120

Pledgee: Beijing technology intellectual property financing Company limited by guarantee

Pledgor: BEIJING NORTHLAND BIOTECH Co.,Ltd.

Registration number: Y2020990000674

PC01 Cancellation of the registration of the contract for pledge of patent right
PC01 Cancellation of the registration of the contract for pledge of patent right

Date of cancellation: 20210118

Granted publication date: 20100120

Pledgee: Beijing technology intellectual property financing Company limited by guarantee

Pledgor: BEIJING NORTHLAND BIOTECH Co.,Ltd.

Registration number: Y2020990000674